Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Umecrine Mood Announces Completion of Patient Recruitment

Published: Friday, December 20, 2013
Last Updated: Friday, December 20, 2013
Bookmark and Share
Patient recruitment in the phase I/II study of Umecrine Mood’s candidate drug for severe premenstrual symptoms.

Umecrine Mood AB has announced that patient recruitment for the ongoing phase I/II study with UC1010 for the treatment of severe premenstrual symptoms (PMDD) has been completed. Umecrine Mood is part of the Karolinska Development portfolio.

“About half of the patients planned for the study have completed the treatment. The remaining participants are currently in treatment or will be treated during the coming months, as soon as diagnosis has been completed. The aim is to present the first results during Q2 2014. We would like to take the opportunity to thank all of you that have showed an interest in participating in the study”, says Karin Ekberg, CEO of Umecrine Mood.

Most women experience some form of symptoms the days before menstruation but in about five percent of young and middle-aged women, the symptoms are so severe that the women are considered to be suffering from PMDD. This implies that the symptoms significantly affect the women’s daily life and relationships to other people.

The basis for the symptoms relates to an altered sensitivity to a breakdown product of a sex hormone that affects the brain's emotional center.

Umecrine Mood is the first company to successfully develop compounds that are proven to reduce the activity of the breakdown product in healthy individuals, and now the selected candidate drug UC1010 is tested in patients for the first time.

"The current treatments of PMDD consist primarily of antidepressant drugs, which are not specifically developed for PMDD. These drugs are not always effective and often cause side effects. There is no doubt that these women are in need of an effective and targeted treatment”, says Karin Ekberg.

The multi-center study is double-blind and placebo controlled and will include about 120 individuals. Coordinating Investigator is Professor Marie Bixo, Institute of Clinical Research and Education, Södersjukhuset, Karolinska Institutet.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Positive Results from an Exploratory Phase I/II Study with UC1010 in PMDD
Results show a significant improvement of symptoms in patients treated with UC1010.
Tuesday, September 23, 2014
Scientific News
Advanced Lymphoma in Remission After T-Cell Therapy
63% of trial participants who recieved two-drug combination chemo plus intermediate dose of engineered T cells went into complete remission.
New Treatment for Immune Cancers
Clinical trial shows new drug holds promise for treating advanced mastocytosis.
Sickle Cell Gene Therapy Passes Test
Researchers found a precision-engineered gene therapy virus reduced sickle-induced red-cell damage in mice with sickle cell disease.
Opening Door to Oesophageal Cancer Targeted Treatments
Scientists have discovered that oesophageal cancer can be classified into three different subtypes.
Inovio Launches Zika Vaccine Trial
Inovio launches Zika vaccine trial in midst of Puerto Rico epidemic to explore early signals of vaccine efficacy.
Vitamin C May Boost Leukemia Treatment
Studies show that supplementing an epigenetic cancer drug with vitamin C enhanced the drug's effectiveness.
New Hope for Zika Treatment Found in Large-Scale Screen of Existing Drugs
Johns Hopkins researchers join collaborative group to screen 6,000 existing drugs in hopes of finding treatments for Zika Virus infection
FINCH Filgotinib Phase 3 Program Initiated
Galapagos NV reports the initiation of the FINCH global Phase 3 program in rheumatoid arthritis patient populations.
Stem Cell Therapy Heals Injured Mouse Brain
A team of researchers has developed a therapeutic technique that dramatically increases the production of nerve cells in mice with stroke-induced brain damage.
Zika Vaccine Testing in Humans
The NAAID has initiated a clinical trail of a vaccine candidate for the prevention of the Zika virus infection.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!